-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the deepening of medical reform, the impact on pharmaceutical companies will continue.
Facing difficulties, a considerable number of companies have sold assets one after another
.
Some companies said that from the perspective of future development, the sale of assets will help companies to grasp the development window of new energy and new materials in a timely manner, accelerate the realization of strategic layout, and enhance the ability of sustainable operation and healthy development
.
Since December, many pharmaceutical companies have been sold
.
On December 18, Kang Enbei issued an announcement on the progress of the public listing and transfer of 42% of the shares of Zhenshiming Company and the announcement of Zhenshiming Company's completion of industrial and commercial change registration
.
According to the announcement, the listing procedure for the 42% equity of Zhenshiming Company was completed, and the transaction amount was RMB 1.
68 billion
.
According to Conbei's preliminary calculations, this transfer of 42% of the shares of Zhenshi Ming is expected to "recover blood" of about 2.
3 billion yuan
.
It is reported that this is not the first time Conba has sold company assets this year
.
On December 27, Zhejiang Conba Pharmaceutical Co.
, Ltd.
also issued an announcement on the progress of Jinhua Conba’s public listing and transfer of 25% equity in Deer Pharmaceuticals
.
The reason for the sale of Sun’s company is that in recent years, Dier Pharmaceuticals has not launched new competitive products, and the competitiveness of existing products has gradually declined.
Its main product, Die Duan Zhuanggu Capsule, has not been included in the medical insurance and will be operated in the future.
There is great uncertainty in the development, so it is listed for sale
.
In addition to Kang Enbei, in the past month, pharmaceutical companies such as Jilin Pharmaceutical Holdings, Jingfeng Pharmaceutical, Jingfeng Pharmaceutical, Yan'an Bikang, Xilong Science, and Meikang Biological have issued relevant announcements on asset sales
.
For example, on December 20, Jilin Pharmaceutical Holdings issued a notice of new progress in the transfer of subsidiaries.
The company signed the "Share Transfer Framework Agreement" with Jilin Baili Pharmaceutical Technology Co.
, Ltd.
on September 27, 2021.
The company plans to hold Jinbao Pharmaceutical 99.
9930% of the company’s shares, the company’s wholly-owned subsidiary Jiangxi Shuanglong holds 0.
0070% of its shares and transferred it to Baili Pharmaceutical
.
Currently still in progress, Jilin Pharmaceutical Holdings will continue to perform information disclosure obligations in accordance with the "Management Measures for the Major Asset Restructuring of Listed Companies" and other relevant regulations
.
On December 15, Jinghua Pharmaceutical issued an announcement stating that it had completed the sale of 100% equity of Sutong Company to its subsidiary Senxuan Pharmaceutical for RMB 7.
37 million
.
On December 10, Yan’an Bikang issued an announcement stating that in order to gradually divest its pharmaceutical business and further improve and adjust the industry and investment structure, Yan’an Bikang and Nanhua Biotech signed the “Asset Acquisition Intention Agreement” and planned to sell Yan’an Bikang to Nanhua Biotech.
The equity of some pharmaceutical companies, pharmaceutical circulation companies and/or the assets corresponding to some production workshops under Kang, the specific scope of assets is subject to negotiation between the two parties
.
On December 7, Hunan Jingfeng Pharmaceutical Co.
, Ltd.
issued an announcement stating that the company would transfer its 1.
8328% equity of Jingze Biomedicine (Hefei) Co.
, Ltd.
, its shareholding company, to Beijing Senheli Technology Development Co.
, Ltd.
for a price of 32 million yuan.
Responsible company
.
After the completion of the transaction, the company will remain holding a 2.
52% stake in Jingze Biological
.
On December 6, Xiangxue Pharmaceutical issued an announcement announcing that it had signed an "Equity Transfer Agreement" with Guangdong Minsheng Investment (Guangzhou) Financial Investment Co.
, Ltd.
, and 100% of its wholly-owned subsidiary, Guangzhou Xiangxue Biomedical Engineering Co.
, Ltd.
The equity was transferred to Yuemin Investment for 18 million yuan
.
An overview of the reasons for the sale of assets by various pharmaceutical companies, the industry said that withdrawing funds to focus on the main business is a word that is often mentioned
.
In addition, these sold assets are often in poor operating conditions, and their performance has declined due to various factors
.
It is reported that in addition to December, many pharmaceutical companies also announced the sale of assets in November, such as Dongyang Sunshine, Renfu Pharmaceutical, Laimei Pharmaceutical, Guangdong Shaxi Pharmaceutical, Hangzhou Huqing Yutang Pharmaceutical, Jinghua Pharmaceutical, Yunnan Baiyao, Ke Fu Medical and Asia Pacific Pharmaceuticals have also released corresponding asset transaction announcements
.
Facing difficulties, a considerable number of companies have sold assets one after another
.
Some companies said that from the perspective of future development, the sale of assets will help companies to grasp the development window of new energy and new materials in a timely manner, accelerate the realization of strategic layout, and enhance the ability of sustainable operation and healthy development
.
Since December, many pharmaceutical companies have been sold
.
On December 18, Kang Enbei issued an announcement on the progress of the public listing and transfer of 42% of the shares of Zhenshiming Company and the announcement of Zhenshiming Company's completion of industrial and commercial change registration
.
According to the announcement, the listing procedure for the 42% equity of Zhenshiming Company was completed, and the transaction amount was RMB 1.
68 billion
.
According to Conbei's preliminary calculations, this transfer of 42% of the shares of Zhenshi Ming is expected to "recover blood" of about 2.
3 billion yuan
.
It is reported that this is not the first time Conba has sold company assets this year
.
On December 27, Zhejiang Conba Pharmaceutical Co.
, Ltd.
also issued an announcement on the progress of Jinhua Conba’s public listing and transfer of 25% equity in Deer Pharmaceuticals
.
The reason for the sale of Sun’s company is that in recent years, Dier Pharmaceuticals has not launched new competitive products, and the competitiveness of existing products has gradually declined.
Its main product, Die Duan Zhuanggu Capsule, has not been included in the medical insurance and will be operated in the future.
There is great uncertainty in the development, so it is listed for sale
.
In addition to Kang Enbei, in the past month, pharmaceutical companies such as Jilin Pharmaceutical Holdings, Jingfeng Pharmaceutical, Jingfeng Pharmaceutical, Yan'an Bikang, Xilong Science, and Meikang Biological have issued relevant announcements on asset sales
.
For example, on December 20, Jilin Pharmaceutical Holdings issued a notice of new progress in the transfer of subsidiaries.
The company signed the "Share Transfer Framework Agreement" with Jilin Baili Pharmaceutical Technology Co.
, Ltd.
on September 27, 2021.
The company plans to hold Jinbao Pharmaceutical 99.
9930% of the company’s shares, the company’s wholly-owned subsidiary Jiangxi Shuanglong holds 0.
0070% of its shares and transferred it to Baili Pharmaceutical
.
Currently still in progress, Jilin Pharmaceutical Holdings will continue to perform information disclosure obligations in accordance with the "Management Measures for the Major Asset Restructuring of Listed Companies" and other relevant regulations
.
On December 15, Jinghua Pharmaceutical issued an announcement stating that it had completed the sale of 100% equity of Sutong Company to its subsidiary Senxuan Pharmaceutical for RMB 7.
37 million
.
On December 10, Yan’an Bikang issued an announcement stating that in order to gradually divest its pharmaceutical business and further improve and adjust the industry and investment structure, Yan’an Bikang and Nanhua Biotech signed the “Asset Acquisition Intention Agreement” and planned to sell Yan’an Bikang to Nanhua Biotech.
The equity of some pharmaceutical companies, pharmaceutical circulation companies and/or the assets corresponding to some production workshops under Kang, the specific scope of assets is subject to negotiation between the two parties
.
On December 7, Hunan Jingfeng Pharmaceutical Co.
, Ltd.
issued an announcement stating that the company would transfer its 1.
8328% equity of Jingze Biomedicine (Hefei) Co.
, Ltd.
, its shareholding company, to Beijing Senheli Technology Development Co.
, Ltd.
for a price of 32 million yuan.
Responsible company
.
After the completion of the transaction, the company will remain holding a 2.
52% stake in Jingze Biological
.
On December 6, Xiangxue Pharmaceutical issued an announcement announcing that it had signed an "Equity Transfer Agreement" with Guangdong Minsheng Investment (Guangzhou) Financial Investment Co.
, Ltd.
, and 100% of its wholly-owned subsidiary, Guangzhou Xiangxue Biomedical Engineering Co.
, Ltd.
The equity was transferred to Yuemin Investment for 18 million yuan
.
An overview of the reasons for the sale of assets by various pharmaceutical companies, the industry said that withdrawing funds to focus on the main business is a word that is often mentioned
.
In addition, these sold assets are often in poor operating conditions, and their performance has declined due to various factors
.
It is reported that in addition to December, many pharmaceutical companies also announced the sale of assets in November, such as Dongyang Sunshine, Renfu Pharmaceutical, Laimei Pharmaceutical, Guangdong Shaxi Pharmaceutical, Hangzhou Huqing Yutang Pharmaceutical, Jinghua Pharmaceutical, Yunnan Baiyao, Ke Fu Medical and Asia Pacific Pharmaceuticals have also released corresponding asset transaction announcements
.
